Biofrontera AG: Biofrontera AG resolves on capital increase and issue of convertible bonds

Leverkusen (pta028/31.10.2016/23:29 UTC+1) The Management Board of Biofrontera AG (FSE: B8F) has resolved today with the approval of the Supervisory Board, to increase the registered capital of the Company from currently EUR 30,347,813 by up to EUR 5,012,950 to up to EUR 35,360,763 by issuing up to 5,012,950 new no-par registered shares with a calculatory participation in the registered capital of EUR 1.00 ("New Shares"). The News Shares are entitled to receive dividends from January 1, 2016.

Shareholders will be offered the statutory subscription right at a ratio of 6:1 via Lang & Schwarz Broker GmbH at a subscription price of EUR 3.00 per New Share.

Furthermore, the Management Board has resolved today, with the approval of the Supervisory Board, to issue up to 49,990 subordinate convertible bonds ("Bonds") with a nominal amount of EUR 100 each and in a total nominal amount of EUR 4,999,000. The bonds mature on December 31, 2020. Each Bond may, subject to the terms and conditions of the Bonds, be converted into ordinary shares of the Company at a calculatory participation in the registered capital of EUR 1.00 and dividend rights from the year of the issue. The conversion price will initially be EUR 3.00 per share, from January 1, 2017 EUR 4.00 per share and from January 1, 2018 EUR 5.00 per share.

Shareholders will be offered the statutory subscription right at a ratio of one (1) Bond per 607 old shares via Lang & Schwarz Broker GmbH at a subscription price of 100 % of the nominal value of EUR 100 per Bond.

The Company intends to use the expected net proceeds of approx. EUR 19.5 million for the repayment of the bond due on January 1, 2017 in an amount of approx. EUR 9 million, as well as to finance the commercialization of Ameluz® in the USA and covering ongoing costs of operations.

The Management Board

Biofrontera AG, Hemmelrather Weg 201, 51377 Leverkusen
ISIN: DE0006046113
WKN: 604611
Kontakt: Biofrontera AG

(end)

Emitter:	Biofrontera AG Hemmelrather Weg 201 51377 Leverkusen Germany
Contact Person:	Investor & public relations
Phone:	+49 (0) 214 87 63 20
E-Mail:	press@biofrontera.com
Website:	www.biofrontera.com
ISIN(s):	DE0006046113 (Share)
Stock Exchange(s):	Regulated Market in Dusseldorf, Frankfurt; Free Market in Berlin, Munich, Stuttgart